Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants

PURPOSE: Galectin-3, a β-galactoside-binding lectin, plays a key role in several cellular pathways involved in chronic inflammation, heart disease and cancer. GB1211 is an orally bioavailable galectin-3 inhibitor, developed to be systemically active. We report safety and pharmacokinetics (PK) of GB1...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslanis, Vassilios, Slack, Robert J., MacKinnon, Alison C., McClinton, Catherine, Tantawi, Susan, Gravelle, Lise, Nilsson, Ulf J., Leffler, Hakon, Brooks, Ashley, Khindri, Sanjeev K., Marshall, Richard P., Pedersen, Anders, Schambye, Hans, Zetterberg, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010643/
https://www.ncbi.nlm.nih.gov/pubmed/36914828
http://dx.doi.org/10.1007/s00280-023-04513-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010643/
https://www.ncbi.nlm.nih.gov/pubmed/36914828
http://dx.doi.org/10.1007/s00280-023-04513-y

Ejemplares similares